Progress of allogeneic hematopoietic stem cell transplantation in treatment of relapsed/refractory acute myeloid leukemia / 白血病·淋巴瘤

ABSTRACT

The prognosis of relapsed/refractory acute myeloid leukemia (AML) is poor,and allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the only possible curative approach for these patients.Several factors including pre-transplant disease burden,cytogenetics/molecular biology,donor type and graft-versus-host disease (GVHD) can affect the efficacy of allo-HSCT.Relapse is the main reason for treatment failure.This review will explore the optimal transplantation time for relapsed/refractory AML patients and risk factors that affect allo-HSCT outcome.